Poolbeg wins South Korean patent for cancer immunotherapy CRS treatment
Poolbeg Pharma has secured a South Korean patent for POLB 001, expanding protection for its approach
Poolbeg Pharma has secured a South Korean patent for POLB 001, expanding protection for its approach